Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus informa una supervivencia estimada a tres años del 48 % con BOT+BAL para cáncer de ovarios recurrente en IGCS 2026

Sunday, October 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. reported a three-year estimated survival rate of 48% for patients with recurrent ovarian cancer in their Phase 1b trial (C-800-01). The study evaluated the efficacy of botensilimab (BOT) combined with balstilimab (BAL), involving over 400 participants. These results highlight the potential of this combination therapy in immuno-oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Estimated three-year survival rate of 48% for recurrent ovarian cancer.
  • Study involved over 400 patients, indicating robust data.
  • Combination therapy shows promise in immuno-oncology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
3.1%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Botensilimab
Phase 2 · Colorectal Cancer

Full Press Release Details

LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), líder en innovación en inmunooncología, anunció hoy los resultados del seguimiento a tres años de la cohorte de cáncer de ovarios de su ensayo C-800-01 de fase 1b, en el que participaron más de 400 pacientes. El estudio evaluó a botensilimab (BOT), el anticuerpo anti-CTLA-4 multifuncional con región Fc potenciada de Agenus, en combinación con balstilimab (BAL), el anticuerpo anti-PD-1 de Agenus. Los resultados, incluida la s

Frequently Asked Questions

What is the survival rate reported by Agenus?

Agenus reported a three-year estimated survival rate of 48%.

How many patients participated in the study?

The study involved over 400 patients.

What therapies were evaluated in the trial?

The trial evaluated botensilimab (BOT) and balstilimab (BAL).

What phase is the C-800-01 trial?

The C-800-01 trial is a Phase 1b study.

ShareAdd on Google
Tags: AGEN Agenus ovarian cancer botensilimab balstilimab clinical trial
Last updated: Oct 4, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BotensilimabPhase 2
Colorectal Cancer →

Catalyst track record

+121%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →